UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 188

Sortiert nach

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1119-1128

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.2927-2930

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

The New England journal of medicine, 2019-08, Vol.381 (8), p.727-738

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Clinical lymphoma, myeloma and leukemia, 2018-11, Vol.18 (11), p.e445-e447

2018

Link zum Volltext

Verfügbarkeit prüfen

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3689-3690

2015

Link zum Volltext

Verfügbarkeit prüfen

Leukaemic vasculitis with myelodysplastic syndrome

The Lancet (British edition), 2015-08, Vol.386 (9992), p.501-502

2015

Link zum Volltext

Verfügbarkeit prüfen

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

BMC cancer, 2021-09, Vol.21 (1), p.993-10, Article 993

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial

Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.296-304.e2

2017

Link zum Volltext

Verfügbarkeit prüfen

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

Blood advances, 2021-03, Vol.5 (5), p.1535-1539

2021

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukemia: prognostic factors and impact on treatment

Discovery medicine, 2011-02, Vol.11 (57), p.115-123

2011

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma

The oncologist (Dayton, Ohio), 2018-04, Vol.23 (4), p.397-e30

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial

Clinical lymphoma, myeloma and leukemia, 2017-03, Vol.17 (5), p.296-304.e2

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.51-52

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Blood, 2021-11, Vol.138 (Supplement 1), p.1635-1635

2021

Link zum Volltext

Verfügbarkeit prüfen

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Blood, 2021-11, Vol.138 (Supplement 1), p.4756-4756

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Leukemia & lymphoma, 2021-09, Vol.62 (11), p.2777-2784

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7558-7558

2016

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Blood, 2019-11, Vol.134 (Supplement_1), p.5569-5569

2019

Link zum Volltext

Verfügbarkeit prüfen

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7308-7310

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Englisch
(187)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(117)
Life Sciences & Biomedicine
(108)
Humans
(100)
Female
(69)
Male
(66)
Middle Aged
(48)
Aged
(42)
Respiratory System
(32)
Chronic Obstructive Pulmonary Disease
(30)
Risk Factors
(23)
Adult
(19)
General & Internal Medicine
(19)
Epidemiology
(18)
Aged, 80 And Over
(17)
Child
(17)
Genomes
(17)
Pulmonary Disease, Chronic Obstructive - Genetics
(17)
Smoking
(17)
Copd
(16)
Genetic Predisposition To Disease
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart

Leukaemic vasculitis with myelodysplastic syndrome

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

Chronic lymphocytic leukemia: prognostic factors and impact on treatment

Whole-exome sequencing in evaluation of patients with venous thromboembolism

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Suchergebnisse filtern